Dr. Park on Challenges With CAR T-Cell Therapies in AML

Name: Dr. Park on Challenges With CAR T-Cell Therapies in AML
Uploaded: 2019-03-01T23:53:00.000Z
Description: Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

March 1, 2019

Jae H. Park, MD

Video

Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses a particular challenge he sees in using chimeric antigen receptor (CAR) T-cell therapies in patients with acute myeloid leukemia (AML).

For now, the data is still too early, but it has been encouraging, Park says, when looking at CD33 and CD123 in patients with AML. However, these targets are not as good as CD19. Park says further investigation is necessary to identify better targets in this space.